

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy

Information for the public

Published: 12 May 2021

www.nice.org.uk

Tafamidis (Vyndaqel) is not normally available on the NHS for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

These organisations can give you advice and support:

- [Cardiomyopathy UK](http://CardiomyopathyUK.org), 0800 018 1024
- [UK ATTR Amyloidosis Patients Association](http://UKATTRAmyloidosisPatientsAssociation.org), info@ttramylodosis.uk

You can also get support from your local [Healthwatch](http://Healthwatch.org).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4129-2